Liraglutide vs Glucagon-like peptide-1
A once-daily GLP-1 receptor agonist; an earlier acylated analog. The incretin that anchors the modern metabolic toolkit. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Liraglutide | Glucagon-like peptide-1 GLP-1 | |
|---|---|---|
| Also known as | Victoza, Saxenda | — |
| Type | Analog | Endogenous |
| Evidence | Established | Established |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | GLP-1 receptor agonist (acylated, 31 aa) | Proglucagon-derived peptide (~30–31 aa) |
| Receptor | GLP-1 receptor (GLP-1R) | GLP-1 receptor (GLP-1R), a class B GPCR |
| Molecular weight | ~3,751.2 Da | ~3,297.7 Da |
| Half-life | ||
| Based on | Glucagon-like peptide-1 | Native hormone |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Liraglutide and Glucagon-like peptide-1?
- Liraglutide is an engineered analog based on Glucagon-like peptide-1; Glucagon-like peptide-1 is an endogenous hormone. Liraglutide signals at GLP-1 receptor (GLP-1R); Glucagon-like peptide-1 signals at GLP-1 receptor (GLP-1R), a class B GPCR.
- How do the half-lives of Liraglutide and GLP-1 compare?
- The reported circulating half-life of Liraglutide is ~13 h; Glucagon-like peptide-1 is ~1–2 min (native; DPP-4 cleaved). These are reference values for the native or representative form — educational only, not dosing advice.
- Is Liraglutide the same as Victoza?
- Victoza, Saxenda are brand names of Liraglutide. This comparison describes the molecules, not branded products.
Prefer the other order? Glucagon-like peptide-1 vs Liraglutide. Or open the interactive comparison tool to add more molecules.